0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Treatment of hypertension during pregnancy: a cohort of pregnancy episodes from the SIDIAP database, Catalonia, Spain

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Hypertension during pregnancy is one of the most frequent causes of maternal and fetal morbimortality. Perinatal and maternal death and disability rates have decreased by 30%, but hypertension during pregnancy has increased by approximately 10% in the last 30 years. This research aimed to describe the pharmacological treatment and pregnancy outcomes of pregnancies with hypertension.

          Methods

          We carried out an observational cohort study from the Information System for the Development of Research in Primary Care (SIDIAP) database. Pregnancy episodes with hypertension (ICD-10 codes for hypertension, I10–I15 and O10–O16) were identified. Antihypertensives were classified according to the ATC WHO classification: β-blocking agents (BBs), calcium channel blockers (CCBs), agents acting on the renin‐angiotensin system (RAS agents), diuretics, and antiadrenergic agents. Exposure was defined for hypertension in pregnancies with ≥2 prescriptions during the pregnancy episode. Descriptive statistics for diagnoses and treatments were calculated.

          Results

          In total, 4,839 pregnancies with hypertension diagnosis formed the study cohort. There were 1,944 (40.2%) pregnancies exposed to an antihypertensive medication. There were differences in mother’s age, BMI, and alcohol intake between pregnancies exposed to antihypertensive medications and those not exposed. BBs were the most used (n = 1,160 pregnancy episodes; 59.7%), followed by RAS agents (n = 825, 42.4%), and CCBs were the least used (n = 347, 17.8%).

          Discussion

          Pregnancies involving hypertension were exposed to antihypertensive medications, mostly BBs. We conduct a study focused on RAS agent use during pregnancy and its outcomes in the offspring.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: found

          2018 ESC/ESH Guidelines for the management of arterial hypertension

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Hypertensive Disorders of Pregnancy

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Prevalence of chronic kidney disease in the United States.

              The prevalence and incidence of kidney failure treated by dialysis and transplantation in the United States have increased from 1988 to 2004. Whether there have been changes in the prevalence of earlier stages of chronic kidney disease (CKD) during this period is uncertain. To update the estimated prevalence of CKD in the United States. Cross-sectional analysis of the most recent National Health and Nutrition Examination Surveys (NHANES 1988-1994 and NHANES 1999-2004), a nationally representative sample of noninstitutionalized adults aged 20 years or older in 1988-1994 (n = 15,488) and 1999-2004 (n = 13,233). Chronic kidney disease prevalence was determined based on persistent albuminuria and decreased estimated glomerular filtration rate (GFR). Persistence of microalbuminuria (>30 mg/g) was estimated from repeat visit data in NHANES 1988-1994. The GFR was estimated using the abbreviated Modification of Diet in Renal Disease Study equation reexpressed to standard serum creatinine. The prevalence of both albuminuria and decreased GFR increased from 1988-1994 to 1999-2004. The prevalence of CKD stages 1 to 4 increased from 10.0% (95% confidence interval [CI], 9.2%-10.9%) in 1988-1994 to 13.1% (95% CI, 12.0%-14.1%) in 1999-2004 with a prevalence ratio of 1.3 (95% CI, 1.2-1.4). The prevalence estimates of CKD stages in 1988-1994 and 1999-2004, respectively, were 1.7% (95% CI, 1.3%-2.2%) and 1.8% (95% CI, 1.4%-2.3%) for stage 1; 2.7% (95% CI, 2.2%-3.2%) and 3.2% (95% CI, 2.6%-3.9%) for stage 2; 5.4% (95% CI, 4.9%-6.0%) and 7.7% (95% CI, 7.0%-8.4%) for stage 3; and 0.21% (95% CI, 0.15%-0.27%) and 0.35% (0.25%-0.45%) for stage 4. A higher prevalence of diagnosed diabetes and hypertension and higher body mass index explained the entire increase in prevalence of albuminuria but only part of the increase in the prevalence of decreased GFR. Estimation of GFR from serum creatinine has limited precision and a change in mean serum creatinine accounted for some of the increased prevalence of CKD. The prevalence of CKD in the United States in 1999-2004 is higher than it was in 1988-1994. This increase is partly explained by the increasing prevalence of diabetes and hypertension and raises concerns about future increased incidence of kidney failure and other complications of CKD.
                Bookmark

                Author and article information

                Contributors
                URI : https://loop.frontiersin.org/people/1461070/overviewRole: Role: Role: Role: Role:
                URI : https://loop.frontiersin.org/people/2417675/overviewRole: Role: Role: Role: Role: Role: Role:
                Role: Role: Role: Role: Role:
                Role: Role: Role: Role: Role:
                Role: Role: Role: Role: Role:
                URI : https://loop.frontiersin.org/people/2103144/overviewRole: Role: Role: Role: Role:
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                17 June 2024
                2024
                : 15
                : 1346357
                Affiliations
                [1] 1 Department of Pharmacotherapy , College of Pharmacy , University of Utah , SLC, UT, United States
                [2] 2 Fundació Institut Universitari per a la Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol) , Barcelona, Spain
                [3] 3 Universitat Autònoma de Barcelona , Bellaterra (Cerdanyola del Vallès), Spain
                [4] 4 Plataforma SCReN , UIC IDIAPJGol , Barcelona, Spain
                [5] 5 Departament de Medicina , Universitat de Barcelona (UB) , Barcelona, Spain
                [6] 6 Àrea del Medicament i Servei de Farmàcia , Gerència d'Atenció Primària Barcelona Ciutat , Institut Català de la Salut , Barcelona, Spain
                [7] 7 Servei d’Atenció Primaria Maresme , Barcelona, Spain
                [8] 8 Institut Català de la Salut , Barcelona, Spain
                Author notes

                Edited by: Clara L. Rodríguez-Bernal, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Spain

                Reviewed by: Salvador Peiró, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Spain

                Colin E. Murdoch, University of Dundee, United Kingdom

                *Correspondence: Maria Giner-Soriano, mginer@ 123456idiapjgol.info
                [ † ]

                ORCID: Ainhoa Gomez-Lumbreras, orcid.org/0000-0002-3916-0402; Carles Vilaplana-Carnerero, orcid.org/0000-0003-3780-4996; Cristina Vedia, orcid.org/0000-0003-4192-3779; Rosa Morros, orcid.org/0000-0001-6752-8748; Maria Giner-Soriano, orcid.org/0000-0003-3750-9233

                Article
                1346357
                10.3389/fphar.2024.1346357
                11215181
                38953107
                0a94807c-9f8e-4f62-85f4-597e2f98d3f7
                Copyright © 2024 Gomez-Lumbreras, Vilaplana-Carnerero, Lestón Vázquez, Vedia, Morros and Giner-Soriano.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 29 November 2023
                : 20 May 2024
                Funding
                Funded by: Departament de Salut, Generalitat de Catalunya , doi 10.13039/501100010552;
                The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was conducted with a grant from IDIAPJGol (this study received funding from the eighth call for SIDIAP grants, 2018 (expedient number 4R18/188) and from the Health Department of the Generalitat de Catalunya in the call corresponding to 2021 for the granting of funding of the Strategic Plan for Research and Innovation in Health (PERIS) 2021–2024, modality Research Projects in Primary Care, expedient number SLT21/21/000068.
                Categories
                Pharmacology
                Original Research
                Custom metadata
                Drugs Outcomes Research and Policies

                Pharmacology & Pharmaceutical medicine
                hypertension,pregnancy-induced,pregnancy outcome,antihypertensive agents,cohort studies,electronic health records,ehr

                Comments

                Comment on this article